Molecular and clinical diversity in primary central nervous system lymphoma

I Hernández-Verdin,E Kirasic,K Wienand,K Mokhtari,S Eimer,H Loiseau,A Rousseau,J Paillassa,G Ahle,F Lerintiu,E Uro-Coste,L Oberic,D Figarella-Branger,O Chinot,G Gauchotte,L Taillandier,J-P Marolleau,M Polivka,C Adam,R Ursu,A Schmitt,N Barillot,L Nichelli,F Lozano-Sánchez,M-J Ibañez-Juliá,M Peyre,B Mathon,Y Abada,F Charlotte,F Davi,C Stewart,A de Reyniès,S Choquet,C Soussain,C Houillier,B Chapuy,K Hoang-Xuan,A Alentorn

DOI: https://doi.org/10.1016/j.annonc.2022.11.002

Abstract:Background: Primary central nervous system lymphoma (PCNSL) is a rare and distinct entity within diffuse large B-cell lymphoma presenting with variable response rates probably to underlying molecular heterogeneity. Patients and methods: To identify and characterize PCNSL heterogeneity and facilitate clinical translation, we carried out a comprehensive multi-omic analysis [whole-exome sequencing, RNA sequencing (RNA-seq), methylation sequencing, and clinical features] in a discovery cohort of 147 fresh-frozen (FF) immunocompetent PCNSLs and a validation cohort of formalin-fixed, paraffin-embedded (FFPE) 93 PCNSLs with RNA-seq and clinico-radiological data. Results: Consensus clustering of multi-omic data uncovered concordant classification of four robust, non-overlapping, prognostically significant clusters (CS). The CS1 and CS2 groups presented an immune-cold hypermethylated profile but a distinct clinical behavior. The 'immune-hot' CS4 group, enriched with mutations increasing the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and nuclear factor-κB activity, had the most favorable clinical outcome, while the heterogeneous-immune CS3 group had the worse prognosis probably due to its association with meningeal infiltration and enriched HIST1H1E mutations. CS1 was characterized by high Polycomb repressive complex 2 activity and CDKN2A/B loss leading to higher proliferation activity. Integrated analysis on proposed targets suggests potential use of immune checkpoint inhibitors/JAK1 inhibitors for CS4, cyclin D-Cdk4,6 plus phosphoinositide 3-kinase (PI3K) inhibitors for CS1, lenalidomide/demethylating drugs for CS2, and enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) inhibitors for CS3. We developed an algorithm to identify the PCNSL subtypes using RNA-seq data from either FFPE or FF tissue. Conclusions: The integration of genome-wide data from multi-omic data revealed four molecular patterns in PCNSL with a distinctive prognostic impact that provides a basis for future clinical stratification and subtype-based targeted interventions.